Avacta Group PLC · LSE:AVCT
Avacta — Investor Presentation (February 2020)
13 slides from Avacta's investor presentation, February 2020
Slide 1: An Investor's Introduction to pre|CISION Chemotherapies
An Investor’s Introduction to pre|CISIONTM Chemotherapies Next generation chemotherapies activated in the tumour February 2020
Slide 2: Disclaimer: Important Notice
Disclaimer: Important Notice No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accuracy, complete
Slide 3: Introduction to pre|CISION Chemotherapies
Introduction to pre|CISION Chemotherapies Chemotherapies are indiscriminate; their effectiveness is limited by side-effects and tolerability for patients. Despite that, the total chemotherapy market will be worth >$50bn by 2024. Avacta’s pre|CISIONTM technology, developed in partnership with Tufts U
Slide 4: The Current Chemotherapy Market
The Current Chemotherapy Market Total chemotherapy market is estimated to be $56.5bn by 2024 (CAGR 11.50%)1 driven by increased cancer detection rates Key Players Multiple Different Drug Classes Sanofi (France), Alkylating Agents Novartis (Germany), Mitotic Inhibitors Pfizer Inc. (U.S.), Antimetabol
Slide 5: pre|CISION Targeted Chemotherapy
pre|CISIONTM Targeted Chemotherapy Avacta’s proprietary pre|CISIONTM chemotherapies are modified to only activate in the tumour minimising the exposure of healthy tissues and reducing toxic side effects Avacta’s pre|CISIONTM An enzyme, which The chemotherapy is only technology is a chemical is only
Slide 6: Lead Programme: AVA6000 Pro-Doxorubicin
Lead Programme: AVA6000 Pro-Doxorubicin Avacta’s lead pre|CISIONTM chemotherapy programme (AVA6000 Pro-doxorubicin) addresses a significant unmet need and could create a multi-billion dollar market Existing Doxorubicin Market • Doxorubicin has been the standard of care treatment for over 40 years fo
Slide 7: Lead Programme: AVA6000 Pro-Doxorubicin
Lead Programme: AVA6000 Pro-Doxorubicin AVA6000 is harmless until it enters the tumour dramatically reducing the exposure of the heart to the active drug and reducing cardiotoxicity AVA6000 pro-doxorubicin • In animal studies : • The maximum tolerated dose of AVA6000 >6x that of standard doxorubicin
Slide 8: AVA6000 Pro-doxorubicin Selectively Delivers Doxorubicin to the Tumour
AVA6000 Pro-doxorubicin Selectively Delivers Doxorubicin to the Tumour pre|CISIONTM pro-doxorubicin has been shown in mouse models to be activated predominantly in the tumour dramatically reducing the exposure of the heart tissue pre|CISIONTM pro-doxorubicin Tumor/Heart Ratio 18:1 Amount of Active D
Slide 9: AVA6000 Pro-doxorubicin Efficacy
AVA6000 Pro-doxorubicin Efficacy In a mouse model of cancer pre|CISIONTM pro-doxorubicin results in 100% survival at 60 days pre|CISIONTM pro-doxorubicin Standard Doxorubicin at the Maximum Dose (No drug) © Avacta Group plc 9
Slide 10: AVA6000 Potential Partnering Opportunities
AVA6000 Potential Partnering Opportunities Companies with Ongoing Clinical Studies Companies with Existing Doxorubicin Products Incorporating Doxorubicin Companies with sales forces and relevant Large pharma testing combinations of antibodies/ doxorubicin commercialization experience and receptor tr
Slide 11: Expansive pre|CISION Pro-drug Pipeline
Expansive pre|CISION Pro-drug Pipeline The pre|CISION technology can be applied to a broad range of other chemotherapies beyond doxorubicin to improve their safety and tolerability, generating a pipeline of proprietary drugs for licensing A pipeline of pre|CISION tumour activated pro-drugs has alrea
Slide 12: Summary
Summary Chemotherapies are indiscriminate; their effectiveness is limited by side-effects and tolerability for patients. Despite that, the total chemotherapy market will be worth >$50bn by 2024. Avacta’s pre|CISIONTM technology, developed in partnership with allows existing chemotherapies to be modi
Slide 13: www.avacta.com
www.avacta.com © Avacta Group plc 13